On August 3, INSILICO fell 5.78% in regular trading, trading at 43.06 HKD/share, with turnover of approximately 517 million HKD. The decline came despite the company announcing on the same day that its co-developed oral NLRP3 inhibitor ISM8969/HT-001 had received NMPA Investigational New Drug approval for the treatment of Parkinson's disease.

The positive pipeline milestone failed to offset broad selling pressure across the Life Sciences Tools and Services sector. GENSCRIPT BIO fell 7.81%, WUXI APPTEC declined 0.19%, WUXI BIO dropped 0.98%, WUXI XDC lost 1.16%, and XTALPI fell 1.61%. The pullback also follows a period of significant gains for INSILICO, which rose nearly 6% on July 31 after receiving FDA Fast Track designation for ISM6331 and posted strong momentum through late July driven by multiple strategic partnerships and a mid-year profit guidance of USD 33.5-39.5 million net profit versus a prior-year loss.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)